Cytokinetics Inc vs S&P Global Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while S&P Global Inc trades at $409.5 (market cap $120.48B). The key difference: S&P Global Inc is far larger — about 11.3× Cytokinetics Inc's market cap, and S&P Global Inc pays a 0.95% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SPGI | |
|---|---|---|
Market Cap | $10.63B | $120.48B |
Sector | Technology | Financials |
52-Week High | $87.26 | $534.79 |
52-Week Low | $34.31 | $370.42 |
Enterprise Value | $10.74B | $131.97B |
Dividend Yield | — | 0.95% |
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →